Dachaigh › Lymphoma Cealla B Mòr Sgaoilte › Colorado
Sgrùdaidhean clionaigeach Lymphoma Cealla B Mòr Sgaoilte ann an Colorado
Tha 19 sgrùdaidhean airson Lymphoma Cealla B Mòr Sgaoilte a’ lorg phàirtichean aig làraichean ann an Colorado.
Bailtean ann an Colorado
Teacsa sgrùdaidh oifigeil (Beurla)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Uchealth North, Fort Collins
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05006716Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Rocky Mountain Cancer Centers, Lone Tree
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06500273Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
A’ fastadhSgrùdadh amharc
Aoisean 0 gu 38 · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06131801A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Lutheran Hospital - Cancer Centers of Colorado ( Site 0180), Golden
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06717347A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Colorado Blood Cancer Institute ( Site 7000), Denver
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07519772A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Rocky Mountain Cancer Centers (RMCC) ( Site 8001), Aurora
- Colorado West Healthcare System-Grand Valley Oncology ( Site 0165), Grand Junction
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06890884A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Colorado Denver - School of Medicine - Anschutz Medical Campus, Aurora
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07101328A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
A’ fastadhÌre 1/2
6 Months – 25 Years · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT06395103Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Rocky Mountain Cancer Centers, LLP, Aurora
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1/2
Aoisean 13 gu 90 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Lùna 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Iuch 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Iuch 2026 · NCT05131022SynKIR-310 for Relapsed/Refractory B-NHL
- Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Gibl 2026 · NCT06544265A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Màrt 2026 · NCT04830137A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Colorado Blood Cancer Institute, Denver
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2025 · NCT05780034A Study of NX-1607 in Adults With Advanced Malignancies
- University of Colorado School of Medicine, Aurora
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2025 · NCT05107674Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.